The Innovative Medicines Initiative

Hugh Laverty
15th June 2017, HESI ANNUAL MEETING, Dublin
IMI – Europe’s partnership for health

**IMI1: 2008-2017**
- €2 bn budget
- 59 projects

**IMI2: 2014-2024**
- €3.3 bn budget
- More ambitious
- More open
- Greater scope

**Partnership 2008-2024**
- €2.5 bn

Goals of IMI 2 programme

- Improve the drug development process by creating tools to assess the efficacy, safety and quality of medicines
- Increase the success rate of clinical trials of new medicines & vaccines
- Speed up the earlier stages of drug development
- Develop new treatments for areas of unmet need
- Develop new biological markers to diagnose diseases and assess treatments
IMI – key concepts

- Non-competitive collaborative research
- Competitive Calls for proposals
- Open collaboration in public-private consortia
  - Data sharing
  - Dissemination of results…
- Industry contribution is in kind
An international, cross-sector community

Over 9,000 researchers working for:
- open collaboration
- improved R&D productivity
- innovative approaches to unmet medical needs

Figures from June 2016
### IMI1 budget distribution per disease area

**Updated January 2017**

<table>
<thead>
<tr>
<th>Disease Area</th>
<th>Budget Distribution</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infectious diseases</td>
<td>671,635,805 €</td>
<td>35%</td>
</tr>
<tr>
<td>Drug Discovery</td>
<td>214,201,208 €</td>
<td>11%</td>
</tr>
<tr>
<td>Brain disorders</td>
<td>188,239,313 €</td>
<td>10%</td>
</tr>
<tr>
<td>Metabolic disorders</td>
<td>119,468,874 €</td>
<td>6%</td>
</tr>
<tr>
<td>Drug safety</td>
<td>115,383,536 €</td>
<td>6%</td>
</tr>
<tr>
<td>Stem cells</td>
<td>77,380,311 €</td>
<td>4%</td>
</tr>
<tr>
<td>Cancer</td>
<td>74,371,979 €</td>
<td>4%</td>
</tr>
<tr>
<td>Data Management</td>
<td>74,291,023 €</td>
<td>4%</td>
</tr>
<tr>
<td>Inflammatory disorders</td>
<td>67,869,654 €</td>
<td>4%</td>
</tr>
<tr>
<td>Biologicals</td>
<td>56,023,072 €</td>
<td>3%</td>
</tr>
<tr>
<td>Vaccines</td>
<td>47,642,719 €</td>
<td>2%</td>
</tr>
<tr>
<td>Geriatrics</td>
<td>47,453,831 €</td>
<td>2%</td>
</tr>
<tr>
<td>Education and Training</td>
<td>39,650,498 €</td>
<td>2%</td>
</tr>
<tr>
<td>Lung diseases</td>
<td>38,499,367 €</td>
<td>2%</td>
</tr>
<tr>
<td>Sustainable chemistry</td>
<td>32,399,640 €</td>
<td>2%</td>
</tr>
<tr>
<td>Drug Delivery</td>
<td>21,336,248 €</td>
<td>1%</td>
</tr>
<tr>
<td>Drug kinetics</td>
<td>18,118,248 €</td>
<td>1%</td>
</tr>
<tr>
<td>Relative effectiveness</td>
<td>14,910,397 €</td>
<td>1%</td>
</tr>
</tbody>
</table>

**Total contributions:** 1,918,875,722 €
IMI2 budget distribution per disease area

Distribution of funding per scientific area

Updated February 2017

- **Infections control**: €316,925,777, 48%
- **Neurodegeneration**: €82,362,270, 12%
- **Diabetes / metabolic disorders**: €64,576,544, 10%
- **Oncology**: €55,277,396, 8%
- **Other**: €54,785,976, 8%
- **Data and knowledge management**: €51,716,147, 8%
- **Translational safety**: €38,251,191, 6%

Total contributions: €663,895,301

BIOVACSAFE - Biomarkers for Enhanced Vaccine Immunosafety [www.biovacsafe.eu](http://www.biovacsafe.eu)

SAFE-T - Safer and Faster Evidence-based Translation [www.imi-safe-t.eu](http://www.imi-safe-t.eu)

MARCAR - Biomarkers and molecular tumour classification for non-genotoxic carcinogenesis [www.imi-marcar.eu/](http://www.imi-marcar.eu/)


eTOX - Integrating bioinformatics and chemoinformatics approaches for the development of Expert systems allowing the in silico prediction of toxicities [www.e-tox.net](http://www.e-tox.net)

TransQST - Translational quantitative systems toxicology to improve the understanding of the safety of medicines [transqst.org](http://transqst.org)
iPIE - Intelligent Assessment of Pharmaceuticals in the Environment [www.i-pie.org](http://www.i-pie.org)

EU2P - European programme in Pharmacovigilance and Pharmacoepidemiology [www.eu2p.org](http://www.eu2p.org)


WEB RADR - Recognising Adverse Drug Reactions [web-radr.eu](http://web-radr.eu)

PREFER - Patient Preferences in benefit risk assessments during the drug life cycle [imi-prefer.eu](http://imi-prefer.eu)

PROTECT - Pharmacoepidemiological research on outcomes of therapeutics by a European consortium [www.imi-protect.eu](http://www.imi-protect.eu)
Stay in touch

- Visit our website www.imi.europa.eu
- Sign up to our newsletter bit.ly/IMInewsletter
- Follow us on Twitter @IMI_JU
- Join our LinkedIn group bit.ly/LinkedInIMI
- E-mail us infodesk@imi.europa.eu
Thank you

Hugh Laverty • Head of Scientific Operations

Hugh.Laverty@imi.europa.eu